4-(4-羟基苯基)-4-氧代丁酸乙酯 | 66123-43-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 4-(4-羟基苯基)-4-氧代丁酸乙酯
• 英文名称: 4-(4-hydroxyphenyl)-4-oxobutanoic acid ethyl ester
• 英文别名: ethyl 4-(4-hydroxyphenyl)-4-oxobutanoate；4-(4-hydroxy-phenyl)-4-oxo-butyric acid ethyl ester；4-(4-Hydroxy-phenyl)-4-oxo-buttersaeure-aethylester；4-(4-Hydroxyphenyl)-4-oxo-butyric acid ethyl ester
• CAS: 66123-43-1
• 化学式: C₁₂H₁₄O₄
• 分子量: 222.241
• InChiKey: JKXVVSUISXKLKO-UHFFFAOYSA-N

物化性质

• 熔点：
  111 °C
• 沸点：
  385.2±22.0 °C(Predicted)
• 密度：
  1.176±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(4-羟基苯基)-4-氧代丁酸乙酯 在 potassium carbonate 作用下， 以 异丙醇 、 丙酮 、 乙腈 为溶剂， 生成 3-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]-4,5-dihydro-1H-pyridazin-6-one
  参考文献：
  名称：

  4,5-Dihydropyridazin-3-one derivatives as histamine H3 receptor inverse agonists

  摘要：

  H3R structure-activity relationships for a new class of 4,5-dihydropyridazin-3-one H3R antagonists/inverse agonists are disclosed. Modification of the 4,5-dihydropyridazinone moiety to block in vivo metabolism identified 4,4-dimethyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one 22 as a lead candidate demonstrating potent in vivo functional H3R antagonism in the rat dipsogenia model and robust wake promoting activity in the rat EEG/EMG model. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.11.037
• 作为产物：
  描述：

  3-(4-甲氧基苯甲酰基)丙酸 在 盐酸 、 氢碘酸 作用下， 以 溶剂黄146 为溶剂， 生成 4-(4-羟基苯基)-4-氧代丁酸乙酯
  参考文献：
  名称：

  蚜虫和蛇毒烷二萜的B / C / D环系统的立体选择性合成

  摘要：

  从普通螺二烯酮（5）中选择性地制备了非对映异构三环[6.3.1.0 1,6 ]十二烷衍生物（3）和（4），对应于Aphidicolane和戊达烷二萜的B / C / D环系统。由邻近的羟基参与介导的区域选择性C–C键形成容易。

  DOI：

  10.1039/c39840000930

文献信息

• Pyridizinone derivatives
  申请人：Hudkins L. Robert

  公开号：US20080027041A1

  公开（公告）日：2008-01-31

  The present invention provides compounds of formula (I*): their use as H 3 inhibitors, processes for their preparation, and pharmaceutical compositions thereof.

  本发明提供了式(I*)的化合物：它们作为H3抑制剂的用途，其制备方法以及药物组合物。
• Stereoselective synthesis of the B/C/D ring systmes of aphidicolane and stemodane diterpenes
  作者：Chuzo Iwata、Toshiya Morie、Naoyoshi Maezaki、Hisafumi Shimamura、Tetsuaki Tanaka、Takeshi Imanishi

  DOI：10.1039/c39840000930

  日期：——

  Diastereoisomeric tricyclo[6.3.1.01,6]dodecane derivatives (3) and (4), which correspond to the B/C/D ring systems of aphidicolane and stemodane diterpenes, were selectively prepared from the common spirodienone (5) by means of facile regioselective C–C bond formation mediated by the neighbouring hydroxy group participation.

  从普通螺二烯酮（5）中选择性地制备了非对映异构三环[6.3.1.0 1,6 ]十二烷衍生物（3）和（4），对应于Aphidicolane和戊达烷二萜的B / C / D环系统。由邻近的羟基参与介导的区域选择性C–C键形成容易。
• Studies on Non-Thiazolidinedione Antidiabetic Agents. 3. Preparation and Biological Activity of the Metabolites of TAK-559
  作者：Hiroshi Imoto、Mitsuharu Matsumoto、Hiroyuki Odaka、Junichi Sakamoto、Hiroyuki Kimura、Masami Nonaka、Yutaka Kiyota、Yu Momose

  DOI：10.1248/cpb.52.120

  日期：——

  Preparation and biological activity of the metabolites of the potent antihyperglycemic and antihyperlipidemic agent, (E)-4-4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]benzyloxyimino}-4-phenylbutyric acid (TAK-559) (1), were investigated. Metabolites M-I (2), M-II (3), M-III (4) and M-IV (5) were synthesized and their biological activities were evaluated by in vitro and in vivo experiments. Compounds 2—4 activate human peroxisome proliferator-activated receptor gamma one (hPPARγ1) and hPPARα, but their activities are weaker than those of TAK-559 (1). Compound 5 only activates hPPARγ1 weakly. TAK-559 (1) showed potent in vivo plasma glucose and triglyceride lowering activities in Wistar fatty rats after intraperitoneal administration, while its metabolites (2—5) showed comparatively weak activities.

  研究了强效抗高血糖和抗高脂血症药物（E）-4-4-[(5-甲基-2-苯基-1,3-噁唑-4-基)甲氧基]苯氧亚胺}-4-苯基丁酸（TAK-559）（1）的代谢物的制备和生物活性。合成了代谢物M-I（2）、M-II（3）、M-III（4）和M-IV（5），并通过体外和体内实验评估了它们的生物活性。化合物2-4能够激活人类过氧化物酶体增殖物激活受体γ1（hPPARγ1）和hPPARα，然而它们的活性弱于TAK-559（1）。化合物5仅能弱激活hPPARγ1。TAK-559（1）在腹腔给药后在Wistar肥胖大鼠中表现出强效的降血浆葡萄糖和甘油三酯活性，而其代谢物（2-5）则展现出相对较弱的活性。
• Leukotriene antagonists
  申请人：Eli Lilly and Company

  公开号：US04874777A1

  公开（公告）日：1989-10-17

  This invention provides benzene derivatives which are leukotriene antagonists, formulations of those derivatives, and a method of using those derivatives for the treatment of conditions characterized by an excessive release of leukotrienes.

  这项发明提供了苯基衍生物，这些衍生物是白三烯拮抗剂，以及这些衍生物的配方，以及使用这些衍生物治疗白三烯过度释放引起的疾病的方法。
• Pyridazinone Derivatives
  申请人：Bacon Edward R.

  公开号：US20110288075A1

  公开（公告）日：2011-11-24

  The present invention is directed to novel pyridazinone derivatives that mediate enzymatic activity. In particular, the compounds may be effective in the treatment of diseases or disease states related to the activity of the histamine H3 receptor, including, for example, neurodegenerative disorders, sleep/wake disorders, attention deficit hyperactivity disorder and cognition/cognitive disorders.

  本发明涉及新型吡啶并咪唑酮衍生物，可介导酶活性。特别是，这些化合物可能在治疗与组胺H3受体活性相关的疾病或疾病状态方面具有有效性，包括神经退行性疾病、睡眠/清醒障碍、注意力缺陷多动障碍和认知/认知障碍等。